Yttrium-90 ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (Zevalin-BEAM) conditioning regimen in relapsed aggressive non-Hodgkin lymphoma

被引：0
|
作者：
Tan, S. M. [1 ]
Lau, N. S. [1 ]
Lim, S. M. [1 ]
Zanapiah, M. [1 ]
Chang, K. M. [1 ]
机构：
[1] Hosp Ampang, Ampang, Myanmar
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S440 / S441
页数：2
相关论文
共 50 条
  • [41] Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
    Gisselbrecht, C.
    Bethge, W.
    Duarte, R. F.
    Gianni, A. M.
    Glass, B.
    Haioun, C.
    Martinelli, G.
    Nagler, A.
    Pettengell, R.
    Sureda, A.
    Tilly, H.
    Wilson, K.
    BONE MARROW TRANSPLANTATION, 2007, 40 (11) : 1007 - 1017
  • [42] Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem cell transplantation in patients with chemorefractory non-Hodgkin lymphoma
    Shimoni, A
    Zwass, T
    Oksman, Y
    Hardan, I
    Shem-Tov, N
    Yerushalmi, R
    Avigdor, A
    Ben-Bassat, I
    Nagler, A
    BONE MARROW TRANSPLANTATION, 2006, 37 : S234 - S234
  • [43] Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
    C Gisselbrecht
    W Bethge
    R F Duarte
    A M Gianni
    B Glass
    C Haioun
    G Martinelli
    A Nagler
    R Pettengell
    A Sureda
    H Tilly
    K Wilson
    Bone Marrow Transplantation, 2007, 40 : 1007 - 1017
  • [44] Dose-escalated radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic haematopoietic cell transplantation in patients with advanced aggressive non-Hodgkin's lymphoma
    Bethge, W. A.
    von Harsdorf, S.
    Bornhaeuser, M.
    Beelen, D.
    Stelljes, M.
    Schwerdtfeger, R.
    Uharek, L.
    Federmann, B.
    Faul, C.
    Vogel, W.
    Dittmann, H.
    Kanz, L.
    Bunjes, D.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S281 - S281
  • [45] Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin®) is a safe and effective treatment option for older patients with relapsed or refractory low-grade non-Hodgkin's lymphoma (NHL)
    Meredith, R
    Schilder, RJ
    Emmanouilides, C
    Vo, K
    Witzig, TE
    Flinn, IW
    Darif, M
    Gordon, LI
    Molina, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S421 - S421
  • [46] Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study
    Puvvada, Soham D.
    Guillen-Rodriguez, Jose M.
    Yan, Jessica
    Inclan, Lora
    Heard, Kara
    Rivera, Xavier I.
    Anwer, Faiz
    Mahadevan, Daruka
    Schatz, Jonathan H.
    Persky, Daniel O.
    ONCOLOGY, 2018, 94 (05) : 274 - 280
  • [47] Role of yttrium-90 Ibritumomab tiuxetan (Zevalin®) in inducing and maintaining complete molecular response in B non Hodgkin's lymphoma patients in clinical complete remission after chemotherapy regimen
    Orciuolo, Enrico
    Buda, Gabriele
    Galimberti, Sara
    Boni, Giuseppe
    Cecconi, Nadia
    Petrini, Mario
    BLOOD, 2007, 110 (11) : 196B - 196B
  • [48] BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma
    Sakellari, Ioanna
    Gavriilaki, Eleni
    Bouziana, Stella
    Constantinou, Varnavas
    Mallouri, Despina
    Vardi, Anna
    Marvaki, Anastasia
    Batsis, Ioannis
    Sotiropoulos, Damianos
    Anagnostopoulos, Achilles
    BONE MARROW TRANSPLANTATION, 2019, 54 (06) : 921 - 923
  • [49] BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma
    Ioanna Sakellari
    Eleni Gavriilaki
    Stella Bouziana
    Varnavas Constantinou
    Despina Mallouri
    Anna Vardi
    Anastasia Marvaki
    Ioannis Batsis
    Damianos Sotiropoulos
    Achilles Anagnostopoulos
    Bone Marrow Transplantation, 2019, 54 : 921 - 923
  • [50] High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma
    Salar, A
    Martino, R
    Altés, A
    Sureda, A
    Brunet, S
    Sierra, J
    HAEMATOLOGICA, 2000, 85 (02) : 217 - 219
12345